Life Sciences Tools and Services
Company Overview of Quintiles Transnational Corp.
Quintiles Transnational Corp. provides clinical, commercial, consulting, and capital solutions to biopharmaceutical industry. The company’s clinical development services cover trial types, such as phase I/IIa, phase II/III, late phase, medical devices, and emerging biopharmaceutical; trial services, including bioanalytical and ADME laboratory, biostatistics, biosimilars, central laboratory, clinical monitoring, data management, ECG, functional, lifecycle safety, patient and investigator recruitment, medical writing, model-based drug development, regulatory, and site ID and start up; data intelligence services comprising reporting and analytics, data-driven processes, data archival and wareho...
4820 Emperor Boulevard
Durham, NC 27703-8411
Founded in 1990
Key Executives for Quintiles Transnational Corp.
Executive Chairman and Member of Executive Committee
Chief Executive Officer of AAA Region and President of AAA Region
Chief Executive Officer of Africa
Compensation as of Fiscal Year 2014.
Quintiles Transnational Corp. Key Developments
Quintiles Presents at Clinical Trial Logistics conference 2014, May-21-2014 02:50 PM
May 18 14
Quintiles Presents at Clinical Trial Logistics conference 2014, May-21-2014 02:50 PM. Venue: Marriott Hotel, Regents Park, 128 King Henry's Road, London, NW3 3ST, United Kingdom. Speakers: Vladimir Anisimov, Senior Strategic Biostatistics Director, Innovation.
BioDelivery Sciences International, Inc. Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the US
Mar 27 14
BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. BUNAVAIL is currently under review at the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of June 7, 2014. Assuming BUNAVAIL is approved, BDSI intends to launch BUNAVAIL in the latter part of third quarter 2014. Under terms of the agreement, Quintiles will provide a range of services to support the launch and subsequent commercialization of BUNAVAIL in the U.S., including a field sales force. Under the direction of BDSI, Quintiles will support the recruitment, training and deployment of a competitively sized sales force capable of reaching the physician base treating the majority of patients with buprenorphine for opioid dependence. In the U.S., nearly 5,000 physicians are responsible for approximately 90% of prescriptions for buprenorphine products for the treatment of opioid dependence according to most recent data from Symphony Health Solutions.
Quintiles Transnational Corp. Presents at Bank of America Merrill Lynch Health Care Conference, May-15-2014 10:40 AM
Feb 28 14
Quintiles Transnational Corp. Presents at Bank of America Merrill Lynch Health Care Conference, May-15-2014 10:40 AM. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Kevin Gordon, Chief Financial Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions